Tower Research Capital LLC TRC lifted its position in Chemed Co. (NYSE:CHE) by 212.7% in the 4th quarter, Holdings Channel reports. The firm owned 3,596 shares of the company’s stock after purchasing an additional 2,446 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Chemed were worth $874,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently made changes to their positions in CHE. JPMorgan Chase & Co. raised its stake in shares of Chemed by 111.5% in the third quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after purchasing an additional 96,237 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Chemed by 173.5% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock worth $19,237,000 after purchasing an additional 60,399 shares during the last quarter. BlackRock Inc. raised its stake in shares of Chemed by 2.4% in the fourth quarter. BlackRock Inc. now owns 2,079,274 shares of the company’s stock worth $505,307,000 after purchasing an additional 49,135 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in shares of Chemed in the fourth quarter worth about $9,296,000. Finally, APG Asset Management N.V. purchased a new position in shares of Chemed in the third quarter worth about $5,657,000. Hedge funds and other institutional investors own 96.16% of the company’s stock.
Shares of Chemed Co. (NYSE CHE) opened at $254.56 on Monday. The company has a market capitalization of $4,064.30, a PE ratio of 28.73 and a beta of 1.13. Chemed Co. has a 1-year low of $170.69 and a 1-year high of $275.83. The company has a current ratio of 0.91, a quick ratio of 0.88 and a debt-to-equity ratio of 0.17.
Chemed (NYSE:CHE) last posted its earnings results on Wednesday, February 14th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.27 by $0.05. The firm had revenue of $428.35 million for the quarter, compared to analyst estimates of $423.83 million. Chemed had a return on equity of 30.04% and a net margin of 5.89%. Chemed’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $2.10 earnings per share.
The business also recently announced a quarterly dividend, which will be paid on Monday, March 19th. Investors of record on Monday, February 26th will be issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, February 23rd. Chemed’s dividend payout ratio (DPR) is 19.28%.
In related news, VP Michael D. Witzeman sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $250.00, for a total transaction of $250,000.00. Following the sale, the vice president now directly owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Naomi C. Dallob sold 950 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $240.38, for a total value of $228,361.00. Following the sale, the vice president now directly owns 9,747 shares in the company, valued at $2,342,983.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,950 shares of company stock worth $3,370,681. 4.90% of the stock is owned by corporate insiders.
CHE has been the subject of several research analyst reports. Royal Bank of Canada raised their price objective on Chemed to $232.00 and gave the stock a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp restated a “hold” rating on shares of Chemed in a research note on Friday, October 27th. TheStreet upgraded Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective for the company in a research note on Thursday, November 2nd. Finally, ValuEngine cut Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $261.33.
ILLEGAL ACTIVITY NOTICE: This article was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://ledgergazette.com/2018/02/19/chemed-co-che-shares-bought-by-tower-research-capital-llc-trc.html.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.